• Facebook
  • X
  • Instagram
MYELOMA360
  • Home
  • MYInsights
  • MYBoard
  • Strategy & Consulting
Select Page

The establishment of a multiple myeloma clinical registry in the Asia-Pacific region: The Asia-Pacific Myeloma and Related Diseases Registry (APAC MRDR)

by | May 3, 2024 | Publications

BMC Med Res Methodol. 2024 May 2;24(1):102. doi: 10.1186/s12874-024-02227-0. ABSTRACT BACKGROUND: Multiple myeloma (MM) is the second most common haematological cancer worldwide. Along with related diseases including monoclonal gammopathy of undetermined significance...

Tunisian Artemisia campestris L.: a potential therapeutic agent against myeloma – phytochemical and pharmacological insights

by | May 3, 2024 | Publications

Plant Methods. 2024 May 2;20(1):59. doi: 10.1186/s13007-024-01185-4. ABSTRACT BACKGROUND: Artemisia campestris L. (AC) leaves are widely recognized for their importance in traditional medicine. Despite the considerable amount of research conducted on this plant...

International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma

by | May 3, 2024 | Publications

Lancet Oncol. 2024 May;25(5):e205-e216. doi: 10.1016/S1470-2045(24)00043-3. ABSTRACT Multiple myeloma remains an incurable disease, despite the development of numerous drug classes and combinations that have contributed to improved overall survival. Immunotherapies...

Daratumumab and antineoplastic therapy versus antineoplastic therapy only for adults with newly diagnosed multiple myeloma ineligible for transplant

by | May 3, 2024 | Publications

Cochrane Database Syst Rev. 2024 May 2;5:CD013595. doi: 10.1002/14651858.CD013595.pub2. ABSTRACT BACKGROUND: Multiple myeloma (MM) is a haematological malignancy that is characterised by proliferation of malignant plasma cells in the bone marrow. For adults ineligible...

Impact of prior treatment on selinexor, bortezomib, dexamethasone outcomes in patients with relapsed/refractory multiple myeloma: Extended follow-up subgroup analysis of the BOSTON trial

by | May 2, 2024 | Publications

Eur J Haematol. 2024 May 1. doi: 10.1111/ejh.14223. Online ahead of print. ABSTRACT OBJECTIVES: To analyze the impact of prior therapies on outcomes with selinexor, bortezomib, and dexamethasone (SVd) versus bortezomib and dexamethasone (Vd) in 402 patients with...

Decreased RNA-binding protein heterogeneous nuclear ribonucleoprotein U improves multiple myeloma sensitivity to lenalidomide

by | May 1, 2024 | Publications

Br J Haematol. 2024 Apr 29. doi: 10.1111/bjh.19468. Online ahead of print. ABSTRACT Multiple myeloma (MM) is an incurable plasma cell cancer in the bone marrow. Immunomodulatory drugs, such as lenalidomide (LEN) and pomalidomide, are backbone agents in MM treatment,...
« Older Entries
Next Entries »

Recent Content

  • Future Perspectives in Multiple Myeloma
  • Patients and Caregivers Aim to Raise Funds for Myeloma Research
  • GPRC5D Bispecific antibody talquetamab-induced dizziness-ataxia syndrome, clinical presentation and management- a case series
  • Symptomatic progression-free survival as an emerging patient-centered endpoint in multiple myeloma: a secondary analysis of MagnetsiMM-3 trial data
  • Blood Test Could Replace Bone Marrow Biopsies in Multiple Myeloma
  • Value of serum-free light chain measurements in response and progression assessment in multiple myeloma with monoclonal protein measurable by electrophoresis
  • Simultaneous whole-body multi-parametric 2-[18F]FDG-PET/MRI in smoldering multiple myeloma assessment: diagnostic and prognostic impact
  • SWIFT-seq enables comprehensive single-cell transcriptomic profiling of circulating tumor cells in multiple myeloma and its precursors
  • Multiple Myeloma: A Modern Look at an Ancient Disease and 2025’s Therapeutic Breakthroughs
  • Can Cilta-Cel Redefine Outcomes in Multiple Myeloma?
  • Facebook
  • X
  • Instagram
©2016-2025 MYELOMA360 & Connect BioMed
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT